BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (NOVEMBER - DECEMBER 2014)

Pharmacogenomics of Warfarin: Clinical Implications

M. Senthilraja

Introduction: However, despite the strong and consistent association data surrounding these variants and a variety of warfarin-related outcomes, there is a paucity of data demonstrating their benefit in clinical practice. The few studies performed to date were either underpowered or lacked adequate control populations and demonstrated inconsistent results2. Although larger, appropriately powered, randomized controlled trials are expected to deliver results within the coming years, these trials might not answer all relevant questions, such as how to incorporate novel anticoagulants, how to measure the cost-effectiveness of testing, and how to evaluate the effect of genetic variants on hard clinical endpoints such as bleeding and thrombosis. Practicing clinician to do in the face of convincing pharmacogenetic association data. 

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright KONGPOSH PUBLICATIONS Pvt. Ltd.